54 results about "Occlusive disease" patented technology

The invention relates to a stent-graft with a bioabsorbable structure and a permanent graft for luminal support and ‘treatment of arterial fistulas, occlusive disease, and aneurysms. The bioabsorbable structure is formed from braided filaments of materials such as PLA, PLLA, PDLA, and PGA and the graft is formed from materials such as PET, ePTFE, PCU or PU.

A tack device for holding plaque against blood vessel walls in treating atherosclerotic occlusive disease is formed as a thin, annular band of durable, flexible material having a plurality of focal elevating elements on its outer annular periphery for holding loose plaque under a spring or other expansion force against a blood vessel wall. The focal elevating elements are designed to exert a holding force on a plaque position while minimizing the amount of material surface area in contact with the plaque or blood vessel wall and reducing the potential of friction with the intraluminal surface. This approach offers clinicians the ability to perform a minimally invasive post-angioplasty treatment and produce a stent-like result without using a stent.

A cardiovascular imaging and functional analysis system and method is disclosed, wherein a dedicated fast, sensitive, compact and economical imaging gamma camera system that is especially suited for heart imaging and functional analysis is employed. The cardiovascular imaging and functional analysis system of the present invention can be used as a dedicated nuclear cardiology small field of view imaging camera. The disclosed cardiovascular imaging system and method has the advantages of being able to image physiology, while offering an inexpensive and portable hardware, unlike MRI, CT, and echocardiography systems.The cardiovascular imaging system of the invention employs a basic modular design suitable for cardiac imaging with one of several radionucleide tracers. The detector can be positioned in close proximity to the chest and heart from several different projections, making it possible rapidly to accumulate data for first-pass analysis, positron imaging, quantitative stress perfusion, and multi-gated equilibrium pooled blood (MUGA) tests..In a preferred embodiment, the Cardiovascular Non-Invasive Screening Probe system can perform a novel diagnostic screening test for potential victims of coronary artery disease. The system provides a rapid, inexpensive preliminary indication of coronary occlusive disease by measuring the activity of emitted particles from an injected bolus of radioactive tracer. Ratios of this activity with the time progression of the injected bolus of radioactive tracer are used to perform diagnosis of the coronary patency (artery disease).

A Cardiovascular imaging and functional analysis system and method employing a dedicated fast, sensitive, compact and economical imaging gamma camera system that is especially suited for heart imaging and functional analysis. The system uses a dedicated nuclear cardiology small field of view imaging camera, allowing image physiology, while offering inexpensive and portable hardware. In some variations, a basic modular design suitable for cardiac imaging with one of several radionucleide tracers is used. The detector is positioned in close proximity to the chest and heart from several different projections, allowing rapid accumulation of data for first-pass analysis, positron imaging, quantitative stress perfusion, and multi-gated equilibrium pooled blood tests. In one variation, a Cardiovascular Non-Invasive Screening Probe system provides rapid, inexpensive preliminary indication of coronary occlusive disease by measuring the activity of emitted particles from an injected bolus of radioactive tracer.

The present invention is a technique and apparatus for acquiring anatomic information used in diagnosing and characterizing abdominal aortic aneurismal disease and the like. This technique provides anatomic information, in the form of images, using a combination of a plurality of magnetic resonance angiography sequences, including a spin-echo and four contrast enhanced (e.g., gadolinium) magnetic resonance angiography sequences. The anatomic images may be used in, for example, pre-operative, operative and post-operative evaluation of aortic pathology, including aneurysms, atherosclerosis, and occlusive disease of branch vessels such as the renal arteries. The gadolinium-enhanced magnetic resonance angiography provides sufficient anatomic detail to detect aneurysms and all relevant major branch vessel abnormalities seen at angiography operation. This technique and apparatus allows for imaging the aorta at a fraction of the cost of conventional aortography and without the risks of arterial catheterization or iodinated contrast.

A microcatheter system that allows for vascular infusion into retinal veins for extended periods of time. The microcatheter system includes a flexible cannula that is inserted into the retinal vein lumen and that remains stably within the retinal vein lumen without being held by a robot, micromanipulator or similar holding devices. The microcatheter system is particularly suitable for the treatment of retinal venous occlusive disease.

A prosthesis is provided for treating aneurysms, occlusive disease of vessels and body organs, and arterio-venous fistulas, occurring in single and bifurcated lumens. The prosthesis comprises an expandable coiled sheet portion having a biocompatible graft, either a sheet or tube, affixed thereto along part or all of the circumference of the coiled sheet portion. The prosthesis has a small delivery profile, making it suitable for use in a variety of body vessels. Methods of making and deploying the prosthesis in single and bifurcated lumens are also provided.

At least one bioactive agent is locally delivered to a location where a stent is implanted within a lumen in a patient's body. The bioactive agent includes a: DNA minor groove binder (such as CC-1065 or Duocarmycin); apocynin; RGD peptide (such as RGDfV); stilbene compound (such as resveratrol); camptothecin; des-aspartate angiotensin I; or ADF; or an analog or derivative thereof; or a combination or blend thereof with at least one other bioactive agent. The bioactive agent is generally locally delivered, such as by elution from the stent. The compounds and methods are of particular benefit for treating or preventing atherosclerosis, stenosis, restenosis, smooth muscle cell proliferation, occlusive disease, or other abnormal lumenal cellular proliferation condition.

The invention relates to a stent-graft with a bioabsorbable structure and a permanent graft for luminal support and treatment of arterial fistulas, occlusive disease, and aneurysms. The bioabsorbable structure is formed from braided filaments of materials such as PLA, PLLA, PDLA, and PGA and the graft is formed from materials such as PET, ePTFE, PCU or PU.

The invention relates to a stent-graft with a bioabsorbable structure and a permanent graft for luminal support and treatment of arterial fistulas, occlusive disease, and aneurysms. The bioabsorbable structure is formed from braided filaments of materials such as PLA, PLLA, PDLA, and PGA and the graft is formed from materials such as PET, ePTFE, PCU or PU.

The present invention is a technique and apparatus for acquiring anatomic information used in diagnosing and characterizing abdominal aortic aneurismal disease and the like. This technique provides anatomic information, in the form of images, using a combination of a plurality of magnetic resonance angiography sequences, including a spin-echo and four contrast enhanced (e.g., gadolinium) magnetic resonance angiography sequences. The anatomic images may be used in, for example, pre-operative, operative and post-operative evaluation of aortic pathology, including aneurysms, atherosclerosis, and occlusive disease of branch vessels such as the renal arteries. The gadolinium-enhanced magnetic resonance angiography provides sufficient anatomic detail to detect aneurysms and all relevant major branch vessel abnormalities seen at angiography operation. This technique and apparatus allows for imaging the aorta at a fraction of the cost of conventional aortography and without the risks of arterial catheterization or iodinated contrast.

Isolated polynucleotide molecules and peptides encoded by these molecules are used in the analysis of human carbamyl phosphate synthetase I phenotypes, as well as in diagnostic and therapeutic applications, relating to a human carbamyl phosphate synthetase I polymorphism. By analyzing genomic DNA or amplified genomic DNA, or amplified cDNA derived from mRNA, it is possible to type a human carbamyl phosphate synthetase I with regard to the human carbamyl phosphate synthetase I polymorphism, for example, in the context of diagnosing and treating hepatic veno-occlusive disease (HVOD) associated with bone marrow transplants.

Isolated polynucleotide molecules and peptides encoded by these molecules are used in the analysis of human carbamyl phosphate synthetase I phenotypes, as well as in diagnostic and therapeutic applications, relating to a human carbamyl phosphate synthetase I polymorphism. By analyzing genomic DNA or amplified genomic DNA, or amplified cDNA derived from mRNA, it is possible to type a human carbamyl phosphate synthetase I with regard to the human carbamyl phosphate synthetase I polymorphism, for example, in the context of diagnosing and treating hepatic veno-occlusive disease (HVOD) associated with bone marrow transplants.

Z maps combined with a standardized stimulus in the form of a targeted arterial partial pressures of carbon dioxide provide suprisingly enhanced images for the assessment of pathological CVR. For example, the z-map assessment of patients with known steno-occlusive diseases of the cervico-cerebral vasculature showed an enhanced resolution of the presence, localization, and severity of the pathological CVR. Z-map have been found to be useful to reduce the confounding effects of test-to-test, subject-to-subject, and platform-to-platform variability for comparison of CVR images showing the importance of combining this analysis with the standardized stimulus.

The kits and methods of the present invention relate to the diagnosis of cardiovascular disorders. In one aspect, the invention discloses a method and a kit for determining whether a subject has a fragile plaque disorder. In one aspect, the invention discloses a method and a kit for determining whether the subject has an occlusive disorder. In one aspect, the invention discloses a method and a kit for determining whether the subject has a restenosis disorder. Other methods of the present invention relate to the selection of therapeutics for a patient with a cardiovascular disease.

The invention relates to the technical field of medical appliances, in particular to a support type artificial venous blood vessel with valve for treating venous reflux diseases and venous return obstruction diseases. The artificial venous blood vessel comprises artificial valve (1) inside the artificial blood vessel, a metal support (2) attached to the outer wall of the artificial blood vessel to support the artificial blood vessel, a metal ring (3) attached to the metal support to support the valve and an artificial blood vessel (4) beyond the range of the support. The artificial venous blood vessel is produced according to the normal vessel valve structure of the human body, the vessel valve can be opened and closed freely, the supporting strength of the support is proper, and the supporting metal ring can maintain the normal state of the vessel valve. The artificial venous blood vessel has the advantages of reasonable structure, low fabrication cost and good histocompatibility, and can be used for valve repair operation for lower limb deep vein, valve repair operation for upper limb deep vein and main vein return obstruction disease of four limbs (especially occlusive diseases) After the vein of the pathologic section is resected, the support type artificial venous blood vessel with the valve is stitched on the normal vein, the operation is simple, and the operative wound is small.

A blood circulation and channel invigorating soup is an obviously effective medicine for curing thromboangitis obliterans, arteriosclerosis occlusive diseases, arteritis, phlebeurysma, vein valve insufficiency, deep venous thrombus, shallow venous thrombus, peripheral neuritis, Raynaud's disease, diabetic gangrene, carotid sclerosis plaque formation, cerebral arteriosclerosis thrombosis, cerebral circulation insufficiency, and various artery and vein blood stasis syndromes. The soup is composed of ginseng, hairy deerhorn, pangolin, leech, earthworm, scorpio, female ground beetle, red sage root, resina draconis, pseudo-ginseng, angelica, cortex moutan, safflower, forsythia, centipede and licorice. The soup has the functions of promoting blood circulation by removing blood stasis, reducing swelling and stopping pain, reducing blood viscosity, dissolving thrombus, dredging blood vessel, and repairing vein valve, and the functions of improving blood circulation, promoting healing abscess and the like, and is used for curing thromboangitis obliterans, arteriosclerosis occlusive diseases, arteritis, phlebeurysma, vein valve insufficiency, deep venous thrombus, shallow venous thrombus, peripheral neuritis, Raynaud's disease, diabetic gangrene, carotid sclerosis plaque formation, cerebral arteriosclerosis thrombosis, cerebral circulation insufficiency, and various artery and vein blood stasis syndromes, can achieve the effect of curing both symptoms and root causes, can achieve the aim of no relapse after recovery; approved by clinic tests, the soup can effectively release the pain of a plurality of patients and receive positive comments from the patients.

Isolated polynucleotide molecules and peptides encoded by these molecules are used in the analysis of human carbamyl phosphate synthetase I phenotypes, as well as in diagnostic and therapeutic applications, relating to a human carbamyl phosphate synthetase I polymorphism. By analyzing genomic DNA or amplified genomic DNA, or amplified cDNA derived from mRNA, it is possible to type a human carbamyl phosphate synthetase I with regard to the human carbamyl phosphate synthetase I polymorphism, for example, in the context of diagnosing and treating hepatic veno-occlusive disease (HVOD) associated with bone marrow transplants.

Technique and apparatus for acquiring anatomic information used in diagnosing and characterizing abdominal aortic aneurismal disease and the like. This technique provides anatomic information, in the form of images, using a combination of a plurality of magnetic resonance angiography sequences, including a spin-echo and four contrast enhanced (e.g., gadolinium) magnetic resonance angiography sequences. The anatomic images may be used in, for example, pre-operative, operative and post-operative evaluation of aortic pathology, including aneurysms, atherosclerosis, and occlusive disease of branch vessels such as the renal arteries. The gadolinium-enhanced magnetic resonance angiography provides sufficient anatomic detail to detect aneurysms and all relevant major branch vessel abnormalities seen at angiography operation. This technique and apparatus allows for imaging the aorta at a fraction of the cost of conventional aortography and without the risks of arterial catheterization or iodinated contrast.

The present invention relates to methods and compositions comprising compounds for the treatment of pathophysiological diseases resulting from inflammatory responses. In particular, the present invention relates to compounds that inhibit or block the production of glycated proteins that induce inflammatory responses associated with signaling in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention relates to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as perlecan. The invention further relates to the use of the compounds in the treatment of vaso-occlusive diseases such as restenosis and atherosclerosis which are characterized by smooth muscle proliferation.

An orally applied medicine of common pueraria flavone for treating coronary heart disease, angina pectoris, the occlusive diseases of vein, artery and retina, etc is prepared from the common pueraria flavone and additive through proportional mixing. Its advantages are high curative effect and low dosage.

Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity compared to wild-type protein C and retain the biological activity of the wild-type human protein C. These derivatives will require either less frequent administration and / or smaller dosage than wild-type human protein C in the treatment of acute coronary syndromes, vascular occlusive disorders, hypercoagulable states, thrombotic disorders and disease states predisposing to thrombosis.

The invention aims at providing a PLGA-S1P nanometer material and a preparation method of a PLGA-S1P nanometer coating stent. The preparation method is characterized by comprising the following steps that S1P is subjected to PLGA coating by a solvent emulsifying method by using an ultrasonic dispersion method, and the ratio of the S1P to PLGA is 1:(10 to 200) (w / w); then, an organic solvent is removed by a method of diffusing an emulsifying agent to water; and finally, freeze-dried powder is prepared by using a freeze-drying concentration method. The PLGA-S1P nanometer particle freeze-dried powder is added into the solvent; after the ultrasonic dissolution, the solution is used as a medicine carrying coating solution; a stainless steel stent is cleanly cleaned; the medicine carrying coating solution is repeatedly sprayed and coated on the surface of the stent by a high-voltage electric spinning method / an ultrasonic spray coating technology; the coating thickness is controlled to be 5 to 20 <mu>m; a de-ionized water / organic solvent volatilization method is used for cleaning; and the PLGA-S1P nanometer coating stent is obtained after the sterilization. The PLGA-S1P nanometer particles are used as the surface coating material of a metal bare stent; and the goal of inhibiting the in-stent restenosis can be achieved. The invention provides a novel method for the interventional therapy for preventing arteriostenosis / occlusion diseases.

The invention relates to application of platycodin D in preparation of medicines for preventing and treating pulmonary hypertension. According to the technical scheme, platycodin D and compositions containing platycodin D are used for treating pulmonary hypertension and cardiovascular related diseases caused by pulmonary hypertension. Experimental researches discover that platycodin D can be used for preventing and treating arbitrary one or more of idiopathic pulmonary hypertension, heritable pulmonary arterial hypertension, drug and toxin related pulmonary hypertension, hazard factor or disease related pulmonary hypertension, pulmonary hypertension caused by pulmonary veno-occlusive disease and (or) pulmonary capillary hemangiomatosis-like diseases, and persistent pulmonary hypertension of newborn.

The invention provides a venous type bracket partly covered by a film. The venous type bracket comprises a naked section, a main body section and a covering film, wherein the naked section and the main body section are tube-shaped objects with a plurality of rows of symmetrical prismatic meshes formed by continuously weaving single memory alloy wires in a crossing manner, the whole covering film is positioned on the main body section, the naked section has no covering film, and the covering film is made of one of polytetrafluoroethylene, polyester and polyamide. The bracket can be used for effectively correcting the stenotic occlusive diseases and protecting the important branch arteries, can be used for the intravascular stent-assisted angioplasty treatment of iliofermoral vein and inferior caval vein stenotic occlusive diseases, and also can be applied to patients suffering from artery stenotic occlusive diseases.

The invention relates to a preparation method of saponin of radix adenophorae as well as an application of the saponin of radix adenophorae, which is prepared in accordance with technical scheme of the invention, in treating medicines for treating pulmonary arterial hypertension and related cardiovascular diseases caused by the pulmonary arterial hypertension. Based upon experimental studies, the saponin of radix adenophorae provided by the invention can take an obvious effect on reducing mean pulmonary arterial pressure (MPAP), right ventricle systolic pressure (RVSP) and right ventricular hypertrophy index (RVHI) of the pulmonary arterial hypertension. The saponin of radix adenophorae can be used for preventing and treating one or more diseases of special pulmonary arterial hypertension, heritable pulmonary arterial hypertension, drug and poison related pulmonary arterial hypertension, risk factor or disease related pulmonary arterial hypertension, pulmonary arterial hypertension caused by pulmonary veno-occlusive disease and (or) pulmonarycapillary hemangiomatosis, and neonatal persistent pulmonary arterial hypertension.

The present invention relates to a bioresorbable scaffold for a vascular stent comprising a nitric oxide agonist and a polymer comprising a lactide, a glycolide and a lactone. The nitric oxide agonist is a statin or a HMG CoA reductase inhibitor. The nitric oxide agonist may be coated on the polymer, incorporated within the polymer or chemically bonded to the polymer. The invention also relates to a method for treating atherothrombosclerotic occlusive disease of an artery comprising implanting into the artery a stent with a bioresorbable scaffold comprising a nitric oxide agonist and a polymer comprising a lactide, a glycolide and a lactone, wherein the nitric oxide agonist is exuded from or released from the bioresorbable scaffold.